Weiss Multi-Strategy Advisers’s Maravai LifeSciences MRVI Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-105,950	Closed	-$1.52M	–	699
2022 Q4	$1.52M	Buy	+105,950	New	+$1.67M	0.04%	419
2022 Q2	–	Sell	-10,742	Closed	-$379K	–	743
2022 Q1	$379K	Buy	+10,742	New	+$360K	0.01%	583

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Weiss Multi-Strategy Advisers's MRVI Position: Q1 2023 in Review

Weiss Multi-Strategy Advisers sold out of Maravai LifeSciences (MRVI) in Q1 2023, closing a stake of 105,950 shares — an estimated $1.52M sold.

Weiss Multi-Strategy Advisers first reported a position in MRVI in Q1 2022 and held it in 2 quarters. The position peaked at $1.52M in Q4 2022. 219 funds tracked by Wall St. Rank hold MRVI as of Q1 2023.

Weiss Multi-Strategy Advisers reported no remaining Maravai LifeSciences position as of Q1 2023 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 105,950 Maravai LifeSciences shares in Q1 2023, an estimated $1.52M.
Weiss Multi-Strategy Advisers first reported a position in Maravai LifeSciences in Q1 2022 and held it in 2 quarters.
Weiss Multi-Strategy Advisers's Maravai LifeSciences position peaked at $1.52M in Q4 2022.
219 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2023.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2023, filed 15 May 2023.